Codex

Centene trades where it does because 2025 exposed how little margin buffer remained once Marketplace risk adjustment, Medicaid acuity, and Part D changes all hit at the same time: HBR jumped, adjusted EPS collapsed, and the goodwill impairment made leverage optics look worse. The single metric most likely to rerate or derate the stock is HBR, because that is where pricing discipline, morbidity, and rate adequacy show up fastest.

Critical Chart

The message is simple: Centene found 160 basis points of SG&A improvement from 2022 to 2025, but HBR worsened 420 basis points. If HBR does not move back toward 89% to 90%, the multiple stays constrained.

Revenue And Earnings Power

The market is not debating scale. It is debating whether 2025 was a bad year that can be repriced away or a new lower earnings base.

Mix Shift

The mix explains the contradiction in the stock. Centene has more exposure to businesses that can grow quickly, but those are also the businesses where morbidity and subsidy design can swing margins hardest.

2025 Intra-Year Pressure

This is the only clean intra-year series in the local data, and it matters. It shows 2025 was not a one-quarter accident; management had to re-underwrite the year in real time before the reserve finally cleared in Q4.

Cash Generation

2024 cash was distorted by PBM and receivable timing, then 2025 snapped back. That partly contradicts the worst reading of the earnings collapse: usable cash recovered, but the market still needs proof that the earnings base is durable.

Capital Allocation

Management retired stock heavily in 2023 and 2024, then pulled back after the earnings reset. That preserved flexibility, but it also tells you management did not treat the late-2025 setup as obviously mispriced.

Balance Sheet Flexibility

The goodwill impairment hurt debt-to-capital optics, but it did not break Centene's regulatory cushion. RBC stayed above 350%, which means the balance-sheet argument is more about flexibility and confidence than near-term solvency.

Peer Context

The numbers confirm that Centene is still a scaled cash generator with real regulatory headroom. They contradict the most bearish version of the story because cash recovered far more than EPS suggests, but they also confirm that margin durability, not scale, is the multiple problem. Next quarter, watch HBR first, then Marketplace risk adjustment and Medicaid rate alignment to see whether 2025 was a reset or the start of a lower-through-cycle margin regime.